Michael Raymund Gonzales, MD
Endocrinology, Diabetes & Metabolism · Reno, NVNPI 1669635785
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,083 of the $89,940 with a category attached, or 64.6%. 49 manufacturers reported payments, led by Corcept Therapeutics at 57.1% of the total. Among endocrinology, diabetes & metabolism clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 859 payments — averaging $104.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$51K
- Bayer$15K
- Mannkind Corporation$5K
- Amgen$4K
- Biomarin Pharmaceutical Inc.$2K
- Novo Nordisk$2K
- plus $11K from 43 others
Across 8 payments — averaging $3946.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$31K
- Corcept Therapeutics$156
What the payments were for
- Consulting fees$3,5634%
- Speaking & faculty fees$58,08365%
- Travel & lodging$7,7789%
- Food & beverage$20,24823%
- Education$2180%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,940 in reported general payments places this provider in the 90th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
See all endocrinology, diabetes & metabolism providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 29 | $1,148,194 |
| OzempicSemaglutide | 684 | $1,016,641 |
| JardianceEmpagliflozin | 453 | $473,273 |
| TrulicityDulaglutide | 231 | $333,432 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 192 | $212,951 |
| Tresiba Flextouch U-200Insulin Degludec | 155 | $181,784 |
| FarxigaDapagliflozin Propanediol | 166 | $165,360 |
| MounjaroTirzepatide | 135 | $158,927 |
| TymlosAbaloparatide | 58 | $152,711 |
| Tresiba Flextouch U-100Insulin Degludec | 197 | $136,590 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 129 | $128,592 |
| MycapssaOctreotide Acetate | 14 | $102,494 |
| RybelsusSemaglutide | 70 | $93,460 |
| KerendiaFinerenone | 70 | $83,603 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $55,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $51,392 | $1,148,19429 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,645 | $1,132,050775 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $816 | $746,593699 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,158 | $492,359366 claims |
| AstraZenecaFarxiga | $1,101 | $165,360166 claims |
| Radius Health, Inc.Tymlos | $717 | $152,71158 claims |
| Chiesi USA, Inc.Mycapssa | $145 | $102,49414 claims |
| BayerKerendia | $15,208 | $83,60370 claims |
| Mannkind CorporationAfrezza | $4,746 | $38,18321 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $904 | $33,76114 claims |
| AbbVieSynthroid | $130 | $20,969206 claims |
| MerckJanuvia | $163 | $14,25514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 75 endocrinology, diabetes & metabolism providers in Nevada.
Other endocrinology, diabetes & metabolism in Reno
- Nitesh KuhadiyaReno$595K
- Lisa AbbottReno$130K
- Claude LardinoisReno$65K
- Sarah MoatsReno$23K
- Daniel CarusoReno$12K
- Robert FredericksReno$10K
- Polina ZykovaReno$7K
- David HowardReno$2K
- James AtchesonReno$2K
- Fadi HendeeReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.